AstraZeneca Champions AI for Lung Cancer Screening, Highlights Impact in Resource-Limited Settings
- By Newsdesk
- Bengaluru
- Apr 02, 2025
AstraZeneca is backing artificial intelligence (AI) as a game-changer in lung cancer detection, particularly in regions with limited medical resources. The pharmaceutical giant presented compelling evidence at the European Lung Cancer Congress (ELCC) 2025, showcasing how AI-powered technology could enhance early diagnosis and improve patient outcomes.
A recent study supported by AstraZeneca found that AI-driven chest X-ray (CXR) analysis can serve as an effective preliminary step before low-dose computed tomography (LDCT), helping identify high-risk individuals and making screening programs more cost-efficient.
Bridging Gaps in Cancer Care
Iskra Reic, Executive Vice President, International, AstraZeneca, emphasized the need for innovative solutions to reduce disparities in cancer care. “To eliminate cancer as a cause of death, we must tackle the disproportionate burden faced by low- and middle-income countries through scalable, tailored solutions,” she said.
Echoing this sentiment, Sanjeev Panchal, Country President and Managing Director of AstraZeneca India Pharma, highlighted AI’s potential to revolutionize healthcare. “By integrating AI into lung cancer detection, especially in resource-constrained settings, we aim to improve early diagnosis and survival rates,” he stated.
AI vs. Traditional Screening
The study utilized Qure.AI’s qXR-LNMS tool to assess lung cancer risk by analyzing incidental pulmonary nodules on chest X-rays. The AI model’s predictions were compared with radiologists' evaluations based on LDCT scans—the current gold standard for diagnosis. Unlike traditional methods, where radiologists manually interpret scans, qXR-LNMS automates nodule and lymph node metastasis detection, potentially speeding up diagnosis and reducing the burden on healthcare professionals.
With lung cancer ranking as the leading cause of cancer-related deaths worldwide—and the fourth most common in India—AstraZeneca’s findings underscore AI’s crucial role in making early detection more accessible. As the healthcare industry increasingly turns to AI for innovative solutions, AstraZeneca’s push for AI-integrated screening could mark a significant step toward reducing lung cancer mortality, particularly in underserved regions.